Your search for evid returned 85 results

Isaralgagene civaparvovec is a recombinant AAV 2/6 vector carrying the cDNA for human α-galactosidase-A.

The approval was based on studies that included adults with moderately to severely active Crohn disease who had an inadequate response to or were intolerant of biologic therapy.

Caldolor contains ibuprofen, a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties.

Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types.

The trial met the criteria for futility and is being discontinued.

Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.

Treatment with dupilumab led to a significant 30% reduction in moderate or severe acute COPD exacerbations.

Tofersen is an investigational antisense medicine that reduces the synthesis of SOD1 protein production.

Rezzayo is expected to be available in the summer of 2023.

Solanezumab is a humanized monoclonal antibody designed to increase clearance of soluble amyloid beta (Aβ) from the brain by binding to aggregated forms of Aβ.